Teprotumumab for Inactive Thyroid Eye Disease? The Jury Is Still Out.

被引：0
|
作者：
Dosiou, Chrysoula [1 ,2 ]
机构：
[1] Stanford Univ, Div Endocrinol, Sch Med, Stanford, CA 94305 USA
[2] Stanford Univ, Div Endocrinol, Sch Med, 300 Pasteur Dr,S025, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2024年 / 109卷 / 09期
关键词：
thyroid eye disease; teprotumumab; MANAGEMENT;
D O I：
10.1210/clinem/dgae052
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e1802 / e1803
页数：2
相关论文
共 50 条
  • [21] Teprotumumab for the treatment of chronic thyroid eye disease
    Ugradar, Shoaib
    Kang, Julia
    Kossler, Andrea L.
    Zimmerman, Erin
    Braun, Jenna
    Harrison, Andrew R.
    Bose, Swaraj
    Cockerham, Kimberly
    Douglas, Raymond S.
    EYE, 2022, 36 (08) : 1553 - 1559
  • [22] Teprotumumab for Optic Neuropathy in Thyroid Eye Disease
    Slentz, Dane H.
    Smith, Terry J.
    Kim, Denise S.
    Joseph, Shannon S.
    JAMA OPHTHALMOLOGY, 2021, 139 (02) : 244 - 247
  • [23] The knowns and unknowns of teprotumumab for thyroid eye disease
    Bednarczuk, Tomasz
    Pearce, Simon H.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (06): : 323 - 325
  • [24] Severe Hyperglycemia with Teprotumumab for Treatment of Thyroid Eye Disease
    Cottom, Savannah
    Barrientez, Brayden
    Melson, Andrew
    CASE REPORTS IN OPHTHALMOLOGY, 2024, 15 (01): : 246 - 249
  • [25] Impact of Teprotumumab on Clinical Practice in Thyroid Eye Disease
    Rachmasari, Kharisa N.
    Toro-Tobon, David
    Wagner, Lilly H.
    Tooley, Andrea A.
    Bradley, Elizabeth A.
    Stan, Marius N.
    ENDOCRINE PRACTICE, 2024, 30 (10) : 937 - 942
  • [26] Teprotumumab for Thyroid Eye Disease-related Strabismus
    Dallalzadeh, Liane O.
    Villatoro, George A.
    Chen, Lillian
    Sim, Myung S.
    Movaghar, Mansoor
    Robbins, Shira L.
    Karlin, Justin N.
    Khitri, Monica R.
    Velez, Federico G.
    Korn, Bobby S.
    Demer, Joseph L.
    Rootman, Daniel B.
    Granet, David B.
    Kikkawa, Don O.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024, 40 (04): : 434 - 439
  • [27] Teprotumumab (Tepezza)-related hyperglycemia in thyroid eye disease
    Lang, Tracy
    Rael, Aaron
    Park, Kristen
    Sudharshan, Rasika
    Chang, Jessica R.
    Zhang-Nunes, Sandy
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [28] Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease
    Kahaly, George.
    Sile, Saba
    Thompson, Elizabeth H.
    Vescio, Thomas
    Perdok, Renee
    Sherman, Jeffrey W.
    Smith, Terry J.
    Douglas, Raymond S.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [29] Effects of Teprotumumab on Eyelid Retraction in Thyroid Eye Disease
    Al-Sharif, Eman M.
    Zhou, Jason
    Shoji, Marissa K.
    Acuff, Kaela
    Liu, Catherine Y.
    Korn, Bobby S.
    Kikkawa, Don O.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2025, 41 (01): : 22 - 27
  • [30] Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
    Kossler, Andrea Lora
    Douglas, Raymond
    Dosiou, Chrysoula
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 : S36 - S46
12345